Stada Arz launches generic Alimta

23 July 2018

German drugmaker Stada Arzneimittel (SAZ: Xetra) will from now on distribute cytostatic drug Pemetrexed STADA in Germany.

The drug is used for treating locally advanced, metastasized and non-small cell lung cancer (NSCLC) and is a generic copyof the product Alimta from US pharma major Eli Lilly (NYSE: LLY).

Alimta generated global sales of around $2.06 billion in 2017. In Germany, this product most recently reported annual sales of around 120 million euros ($140.5 million). In contrast to the original product, Pemetrexed STADA is supplied not in powder form, but ready-to-use as a concentrate for preparing a solution for infusion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK